Institution Directory

Clinical trials at Memorial Sloan Kettering Cancer Center

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1675

Shown on this page

Current sort

Live official records

Conditions: HLA-A*0201 Positive Cells Present, Clear Cell Sarcoma (CCS)
Interventions: Physician's Choice, Tebentafusp; Drug
Lead sponsor: Sarcoma Alliance for Research through Collaboration; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Conditions: Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Lutetium Lu 177 Vipivotide Tetraxetan, Biospecimen Collection, Patient Monitoring, Computed Tomography, Bone Scan, PSMA PET Scan, MRI, Questionnaire Administration; Drug · Procedure · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1,524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 138
States / cities: Anchorage, Alaska • Bakersfield, California • Irvine, California + 114 more

Conditions: Hodgkin Lymphoma
Interventions: pembrolizumab, doxorubicin, vinblastine, dacarbazine, cyclophosphamide, vincristine, prednisone/prednisolone, bleomycin, etoposide, Radiotherapy (RT); Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 3 Years to 25 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 47
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 41 more

Conditions: PSMA PET-Positive Castration-Resistant Prostate Cancer
Interventions: In-111 rosopatamab tetraxetan, 45 kBq/kg Ac-225 rosopatamab tetraxetan, 45 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan, 60 kBq/kg Ac-225 rosopatamab tetraxetan, Single dose 22 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan, Single dose 34 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan, Single dose 45 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan, 55 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan, 60 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan; Biological
Lead sponsor: Convergent Therapeutics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 9
States / cities: San Diego, California • Boston, Massachusetts • St Louis, Missouri + 4 more

Conditions: Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Oligometastatic Colorectal Carcinoma
Interventions: Stereotactic Ablative Radiotherapy, Resection, Microwave Ablation, Chemotherapy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 188
States / cities: Kingman, Arizona • Phoenix, Arizona • Beverly Hills, California + 146 more

Conditions: Astrocytoma, IDH-Mutant, Grade 3
Interventions: Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Pencil Beam Scanning, Intensity-Modulated Proton Therapy, Temozolomide, Vorasidenib, Placebo Administration, Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration; Radiation · Procedure · Drug + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 12 Years and older
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2040
U.S. locations: 152
States / cities: Bakersfield, California • Duarte, California • Dublin, California + 119 more

Conditions: Oligometastatic Breast Carcinoma, Breast Cancer, Metastatic Breast Cancer, Metastatic Breast Carcinoma, ER+ Breast Cancer, HER2+ Breast Cancer
Interventions: Stereotactic body radiotherapy; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more

Conditions: Lung Cancer, Lung Cancer Stage II, Lung Cancer Stage III
Interventions: Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Certolizumab, Nivolumab, Paclitaxel; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Interventions: larotrectinib(Vitrakvi, BAY2757556); Drug
Lead sponsor: Bayer; Industry
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 51
States / cities: Mesa, Arizona • Los Angeles, California • Newport Beach, California + 42 more

Conditions: Renal Cell Carcinoma
Interventions: HC-7366, Belzutifan; Drug
Lead sponsor: HiberCell, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 21
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more

Conditions: Appendix Cancer, Colorectal Cancer
Interventions: Cytoreductive Surgery, HIPEC with Mitomycin-C, EPIC with FUDR and Leucovorin; Procedure · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 9
States / cities: Miami, Florida • St Louis, Missouri • Basking Ridge, New Jersey + 6 more

Conditions: Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor
Interventions: Biospecimen Collection, Carboplatin, Computed Tomography, Echocardiography Test, High-Dose-Rate Vaginal Cuff Brachytherapy, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Multigated Acquisition Scan, Paclitaxel, Survey Administration, Trastuzumab/Hyaluronidase-oysk; Procedure · Drug · Radiation + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 409
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 307 more

About this Memorial Sloan Kettering Cancer Center institution page

What this page lists: ClinicalTrials.gov records that list Memorial Sloan Kettering Cancer Center in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Memorial Sloan Kettering Cancer Center

Filter and sort this campus

Live official records

A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

About this Memorial Sloan Kettering Cancer Center institution page